Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer
The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.
United States Shannonn Westin Society Of Gynecologic Oncology Department Of Gynecologic Oncology University Of Texas Md Anderson Cancer Center Division Of Surgery
Source: onclive.com